

Silver State Scripts Board Made Changes to the Preferred Drug List Effective August 1, 2026

The Silver State Scripts Board (SSSB) met on June 18, 2026, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective August 1, 2026.

The complete PDL is posted on the ["Preferred Drug List"](#) webpage.

Drug Class/Program	Changes
Short-Acting Beta Adrenergics (SABAs)	- Ventolin HFA moved from preferred to non-preferred - Proventil HFA and ProAir Digihaler removed from PDL due to product discontinuation
Anti-Hypoglycemic Agents	- Gvoke pen moved from non-preferred to preferred - All glucagon emergency kits now preferred - Zegalogue removed from PDL due to product discontinuation
Incretin Mimetics and Combinations	- Mounjaro moved from non-preferred to preferred with prior authorization - Ozempic tablet placed as preferred with prior authorization - Byetta and Bydureon BCise removed from PDL due to product discontinuation
Platelet Inhibitors	- Brilinta moved from preferred to non-preferred - Ticagrelor (generic for Brilinta) moved from non-preferred to preferred with prior authorization - Yosprala and Zontivity removed from the PDL due to no longer participating in the Medicaid Drug Rebate Program (MDRP)
Rapid-Acting Insulins	- Insulin aspart (generic for Novolog) removed from PDL due to product discontinuation Humalog 100 unit/mL formulations moved from non-preferred to preferred Humalog 200 unit/mL will remain non-preferred - Novolog moved from preferred to non-preferred
Pre-Mixed Insulin Combinations	Insulin aspart/insulin aspart protamine (generic for Novolog 70/30) removed from PDL due to product discontinuation
Sodium-Glucose Co-Transporter 2 (SGLT2)	- Invokamet moved from preferred to non-preferred - Invokana moved from preferred to non-preferred

Inhibitors and Combination	• Qtern brand removed from the PDL due to product discontinuation • Dapagliflozin/saxagliptin (generic for Qtern) placed as non-preferred
Immunomodulators: Atopic Dermatitis	• Ebglyss moved from non-preferred to preferred with prior authorization • Nemluvio moved from non-preferred to preferred with prior authorization • Vtama placed as non-preferred
Functional Gastrointestinal Disorder Drugs: Constipation-Related	• Movantik moved from preferred to non-preferred • Amitiza removed from the PDL due to product discontinuation
Topical Anti-infectives: Topical Scabicides	• Spinosad (generic for Natroba) moved from non-preferred to preferred • Crotan and Pruradik (both crotamiton 10% lotions) placed as non-preferred • Piperonyl butoxide/pyrethrins placed as preferred • Nix, Rid, and Ulesfia removed from PDL due to no longer participating in the Medicaid Drug Rebate Program (MDRP) • Lindane removed from the PDL due to product discontinuation
Targeted Immunomodulator	• Hadlima moved from non-preferred to preferred with prior authorization • Adalimumab-adbm no longer broken out by manufacturer, all adalimumab-adbm moved to non-preferred • Avtozma placed as non-preferred • Kevzara moved from preferred to non-preferred • Pyzchiva moved from preferred to non-preferred • Yesintek moved from preferred to non-preferred • Starjemza placed as preferred with prior authorization • Selarsdi moved from non-preferred to preferred with prior authorization • Imuldosa placed as non-preferred • Ustekinumab-aaaz placed as non-preferred • Otezla IR tablet will remain preferred • Otezla XR and XR initiation pack placed as non-preferred • Cosentyx moved from preferred to non-preferred • Taltz moved from non-preferred to preferred with prior authorization

	Siliq removed from the PDL due to no longer participating in the Medicaid Drug Rebate Program (MDRP)
Prolia and Biosimilars	- New class added to PDL - Enoby placed as preferred with prior authorization - Bildyos, Bosaya, Conexence, Jubbonti, Prolia, and Stoboclo placed as non-preferred
Xgeva and Biosimilars	- New class added to the PDL - Xtrenbo placed as preferred with prior authorization - Aukelso, Bilprevda, Bomynta, Osenvelt, Wyost, and Xgeva placed as non-preferred
Duchenne Muscular Dystrophy (DMD) Corticosteroids	- New class added to the PDL - Emflaza tablet placed as preferred with prior authorization - Deflazacort suspension, deflazacort tablet, Emflaza suspension, Jaythari suspension, Jaythari tablet, Kymbee suspension, Kymbee tablet, and Pyquvi suspension placed as non-preferred